AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03599518
Drug: DS-1205c
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1205c 200 mg capsule for oral administration
Trial: NCT01596712
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
Trial: NCT01596712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
Trial: NCT01658605
Drug: GSK1605786
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily administered orally
Trial: NCT01527877
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed.
Trial: NCT02517398
Drug: MSB0011359C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Trial: NCT00429182
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
Trial: NCT00050102
Drug: MDX-010 (CTLA-4)
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04140786
Drug: Gentamicin Sulfate, Injectable
RxNorm normalized name: Gentamicin Sulfate, Injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
Trial: NCT00364650
Drug: Probiotic Supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules twice daily
Trial: NCT02781571
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg tablet administered orally once daily
Trial: NCT01881282
Drug: Mayinglong Musk Hemorrhoid Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
Trial: NCT01165125
Drug: FF / GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mcg/25mcg Novel DPI
Trial: NCT02151656
Drug: F17464
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02151656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03420144
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
Trial: NCT00006261
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
Trial: NCT00006261
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT01607125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, orally, once daily for 13 to 14 days
Trial: NCT03096327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
Trial: NCT02065349
Drug: ASP8477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02065349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02607410
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Trial: NCT00703885
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Trial: NCT02625090
Drug: UCB0942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral
Trial: NCT02423538
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Trial: NCT02423538
Drug: SHR0302 placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Trial: NCT02615119
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Trial: NCT03215381
Drug: [11C]AZD1390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[11C\]AZD1390
Trial: NCT03685084
Drug: AAI101 i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Trial: NCT03685084
Drug: Saline 0.9% infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle infusion
Trial: NCT00629499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 of IV cyclophosphamide
Trial: NCT02730572
Drug: Concerta AG formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
Trial: NCT02730572
Drug: Concerta EG formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
Trial: NCT04105998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04105959
Drug: RIST4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 oral solution
Trial: NCT04105959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT02243683
Drug: AX-024.HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542126
Drug: Decapeptyl 0.1 mg after embryo transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
Trial: NCT02311881
Drug: Paracetamol 1000 mg SR tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
Trial: NCT02311881
Drug: Paracetamol 665 mg SR tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
Trial: NCT02311881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
Trial: NCT04704713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00550186
Drug: HaemoHES 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00252330
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02776605
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
Trial: NCT02776605
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
Trial: NCT02776605
Drug: ARA-C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
Trial: NCT01484496
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Trial: NCT03773302
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Trial: NCT02478242
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02735551
Drug: Long Acting Reversible Contraception (LARC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
Trial: NCT04388215
Drug: D326(placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: D337(placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: D013(placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT02168101
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.
Trial: NCT00088270
Drug: 5-Fluorouracil/Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00847899
Drug: AR9281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR9281 taken in BID dosing regimen for 28 days
Trial: NCT00847899
Drug: AR9281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR9281 taken in TID dosing regimen for 28 days
Trial: NCT00847899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken in BID dosing regimen for 28 days
Trial: NCT00847899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken in TID dosing regimen for 28 days
Trial: NCT01799057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
Trial: NCT03813875
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
Trial: NCT01440114
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
Trial: NCT01378650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo one tablet matching for cilostazol twice a day for 4 weeks.
Trial: NCT01127984
Drug: tissucol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
Trial: NCT04608110
Drug: ASTX030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
Trial: NCT00903279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
Trial: NCT01057693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as capsules and given 3 times daily.
Trial: NCT01804049
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
Trial: NCT03443089
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
Trial: NCT03443089
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
Trial: NCT01457664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to RO4995819 once daily for 14 days
Trial: NCT01457664
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO4995819 doses once daily for 14 days
Trial: NCT01527240
Drug: Ciclosprin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
Trial: NCT01527240
Drug: Injectable Saline Solution.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Solution is administered once 15 min after thrombolysis.
Trial: NCT00568594
Drug: APL180
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01419600
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose Inhaled IMP via Turbuhaler
Trial: NCT01419600
Drug: Placebo to match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose Inhaled Placebo via Turbuhaler
Trial: NCT04340388
Drug: Antiretroviral/Anti HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
Trial: NCT01453491
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
Trial: NCT00221546
Drug: Giving DHA-rich supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving DHA-rich supplement to patients.
Trial: NCT03705559
Drug: Vaporized Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Marijuana or Placebo, administered through vaporizer
Trial: NCT03705559
Drug: Opioid Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Opioid Agonist or Placebo, administered intranasally
Trial: NCT00681395
Drug: ABT-143
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 6 days
Trial: NCT00681395
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for six days
Trial: NCT00681395
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily for 6 days
Trial: NCT01094977
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01833858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
Trial: NCT00295282
Drug: MDX-1100 (anti-CXCL10 human monoclonal antibody)
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
Trial: NCT02948582
Drug: Glycopyrrolate Inhalation Solution12.5μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
Trial: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 50μg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
Trial: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 100μg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
Trial: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 200μg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
Trial: NCT02948582
Drug: Glycopyrrolate Inhalation Solution 400μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
Trial: NCT02948582
Drug: Placebo 0.5mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5mL via eFlow, once daily
Trial: NCT00334568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01925768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
Trial: NCT01308359
Drug: IV glucose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml glucose 5% within 30 minutes
Trial: NCT00004891
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02967679
Drug: MD1003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02985177
Drug: INF2.0 + IBU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics
Trial: NCT02985177
Drug: INF1.0 + IBU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics
Trial: NCT00473876
Drug: Matched Placebo (Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar dosing regime as active comparator
Trial: NCT02168595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00124280
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01818726
Drug: ICL670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
Trial: NCT01818726
Drug: Chelation
RxNorm normalized name: MULTIVIT/MIN, HERBAL CHELATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
Trial: NCT01818726
Drug: No chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
Trial: NCT01918865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no